Pembrolizumab infusion

DRUG2 trials

Sponsors

Abramson Cancer Center at Penn Medicine

Conditions

Breast CancerRenal Cell Carcinoma

Early Phase 1

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

RecruitingNCT05733715

Abramson Cancer Center at Penn MedicineRenal Cell Carcinoma

Start: 2023-05-03End: 2028-12-01Target: 30Updated: 2026-08-13

Phase 1

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

Active, not recruitingNCT04454528

Abramson Cancer Center at Penn MedicineBreast Cancer

Start: 2020-12-07End: 2027-08-01Target: 27Updated: 2026-03-10

Related Papers

Preoperative combination radiotherapy (RT) and immune checkpoint inhibitor (ICI) in early-stage breast cancer: Influence of RT and ICI treatment sequencing (NCT04454528 post-hoc analysis).

Journal of Clinical Oncology2026-05-27

Abstract PS4-07-15: A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study

Clinical Cancer Research2026-02-17

644 Major pathologic response after a single radiotherapy fraction + a single pembrolizumab dose given preoperatively in patients with cT1N0 triple negative breast cancer (TNBC) – preliminary results of a phase 1b/2 study (NCT04454528)

Regular and Young Investigator Award Abstracts2022-11-012 citations